{"id":"mitozantrone","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute disease of cardiovascular system","Acute infectious disease","Anemia","Bacterial infectious disease","Bone marrow depression","Breastfeeding (mother)","Chronic heart failure","Disease of liver","Hepatic failure","Left heart failure","Leukopenia","Mycosis","Neutropenic disorder","Pregnancy, function","Radiation oncology AND/OR radiotherapy","Seizure disorder","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase"},"_scrapedAt":"2026-03-28T02:01:42.282Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acute myeloid leukemia, disease","diseaseId":"acute-myeloid-leukemia-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Metastatic Prostate Carcinoma","diseaseId":"metastatic-prostate-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Relapsing remitting multiple sclerosis","diseaseId":"relapsing-remitting-multiple-sclerosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT03182244","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2017-10-25","conditions":"AML With FLT3 Mutation","enrollment":276},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT06660368","phase":"PHASE2","title":"BCL2i CLAG-M in R/R Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-26","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":52},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07354698","phase":"PHASE4","title":"Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-01","conditions":"Papillary Thyroid Cancer","enrollment":114},{"nctId":"NCT06429449","phase":"PHASE1","title":"Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-21","conditions":"Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":30},{"nctId":"NCT05848687","phase":"PHASE1, PHASE2","title":"TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II","status":"RECRUITING","sponsor":"Tanja Andrea Gruber","startDate":"2023-11-03","conditions":"Lymphoblastic Leukemia","enrollment":90},{"nctId":"NCT03258320","phase":"PHASE2, PHASE3","title":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Prostate Cancer Patients","enrollment":300},{"nctId":"NCT07093710","phase":"PHASE1, PHASE2","title":"Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-27","conditions":"Peripheral T Cell Lymphoma","enrollment":101},{"nctId":"NCT05657639","phase":"PHASE2","title":"CAV Regimen for R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT07288814","phase":"PHASE1, PHASE2","title":"Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-12-08","conditions":"Relapsed or Refractory Peripheral T Cell Lymphoma","enrollment":43},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm","enrollment":1645},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT02879643","phase":"PHASE1","title":"Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2017-01-31","conditions":"ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute","enrollment":29},{"nctId":"NCT03118466","phase":"PHASE2","title":"Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-09-25","conditions":"AML","enrollment":41},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT07168317","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-08-01","conditions":"New Diagnosed Angioimmunoblastic T-Cell Lymphoma","enrollment":40},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT06499025","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)","status":"ENROLLING_BY_INVITATION","sponsor":"BGI, China","startDate":"2024-02-01","conditions":"AML, t(8;21), Neoantigen","enrollment":16},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":"Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome","enrollment":280},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT07058103","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-04-01","conditions":"Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT07028086","phase":"PHASE2","title":"VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-20","conditions":"Acute Myeloid Leukemia, Myeloid Sarcoma","enrollment":48},{"nctId":"NCT05054543","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","status":"TERMINATED","sponsor":"Apollomics Inc.","startDate":"2021-11-17","conditions":"Relapsed/Refractory AML","enrollment":140},{"nctId":"NCT04839341","phase":"PHASE1","title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","status":"COMPLETED","sponsor":"Apollomics Inc.","startDate":"2021-02-24","conditions":"Relapsed/Refractory AML","enrollment":12},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT05941585","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-08-08","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT04668690","phase":"PHASE3","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-04-13","conditions":"Peripheral T Cell Lymphoma","enrollment":193},{"nctId":"NCT01184898","phase":"NA","title":"Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"AML","enrollment":36},{"nctId":"NCT06244368","phase":"PHASE2","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-01-17","conditions":"Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":115},{"nctId":"NCT06594640","phase":"PHASE1, PHASE2","title":"R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-30","conditions":"Diffuse Large B-cell Lymphoma","enrollment":108},{"nctId":"NCT05299164","phase":"PHASE1","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-05-15","conditions":"Non Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT06953739","phase":"PHASE3","title":"A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":60},{"nctId":"NCT00410423","phase":"PHASE1, PHASE2","title":"Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Relapsed Acute Leukemia, Refractory Acute Leukemia","enrollment":55},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT06921044","phase":"PHASE2","title":"A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Xiaohui He","startDate":"2025-04-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":33},{"nctId":"NCT06760039","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-10","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":112},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT04778410","phase":"PHASE2","title":"Study of Magrolimab Combinations in Participants With Myeloid Malignancies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Myeloid Malignancies","enrollment":54},{"nctId":"NCT06757478","phase":"","title":"A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-05-01","conditions":"Lymphoma Patient","enrollment":30},{"nctId":"NCT05464433","phase":"PHASE1, PHASE2","title":"Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-23","conditions":"Extranodal Natural Killer T Cell Lymphoma","enrollment":46},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT03839446","phase":"PHASE2","title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","status":"COMPLETED","sponsor":"Robert Redner, MD","startDate":"2019-02-28","conditions":"Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT05603884","phase":"PHASE2","title":"VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-12-01","conditions":"Leukemia, Myeloid, Acute, AML Stage, Adult","enrollment":66},{"nctId":"NCT06472713","phase":"PHASE2","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2024-07-20","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT06761417","phase":"PHASE2","title":"A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-01","conditions":"Solid Tumors, Children, Adolescents","enrollment":49},{"nctId":"NCT06758726","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-12-31","conditions":"AML","enrollment":20},{"nctId":"NCT05958719","phase":"PHASE2","title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-02","conditions":"Peripheral T Cell Lymphoma, Epigenetic Repression","enrollment":37},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05904106","phase":"PHASE2","title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2024-04-07","conditions":"Acute Myeloid Leukemia","enrollment":146},{"nctId":"NCT03441048","phase":"PHASE1","title":"Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-05-22","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06621199","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-08","conditions":"Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT02484391","phase":"PHASE1","title":"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-09","conditions":"Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06007911","phase":"PHASE1","title":"Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2024-08-31","conditions":"Relapsed Adult AML, Refractory AML","enrollment":""},{"nctId":"NCT05551598","phase":"PHASE2","title":"Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2022-11-28","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":46},{"nctId":"NCT03616470","phase":"PHASE3","title":"Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"GlycoMimetics Incorporated","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia","enrollment":388},{"nctId":"NCT06514313","phase":"PHASE2","title":"Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.","status":"RECRUITING","sponsor":"Yizhuo Zhang","startDate":"2024-07-03","conditions":"Soft Tissue Sarcoma","enrollment":110},{"nctId":"NCT05620862","phase":"PHASE1","title":"Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-10-25","conditions":"Pediatric Solid Tumor","enrollment":68},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06486337","phase":"PHASE2","title":"CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"NHL","enrollment":197},{"nctId":"NCT02400281","phase":"PHASE1, PHASE2","title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT06475287","phase":"PHASE2","title":"HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-20","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06447090","phase":"PHASE2","title":"VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-12","conditions":"Relapse Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06434662","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-02-29","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":34},{"nctId":"NCT06433362","phase":"PHASE2","title":"CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-01","conditions":"Peripheral T Cell Lymphoma","enrollment":115},{"nctId":"NCT06385808","phase":"NA","title":"Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-05-01","conditions":"Relapse Leukemia, Refractory Acute Myeloid Leukemia, Conditioning","enrollment":37},{"nctId":"NCT06345365","phase":"PHASE3","title":"MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2024-01-18","conditions":"Acute Myeloid Leukaemia","enrollment":154}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"MYELODYSPLASTIC SYNDROME"},{"count":2,"reaction":"NEUTROPENIA"},{"count":2,"reaction":"NEUTROPENIC SEPSIS"},{"count":2,"reaction":"PANCYTOPENIA"},{"count":1,"reaction":"ACUTE LEUKAEMIA"},{"count":1,"reaction":"ASCITES"},{"count":1,"reaction":"ATAXIA"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"B-CELL LYMPHOMA"},{"count":1,"reaction":"BONE MARROW FAILURE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":119,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Mitozantrone","genericName":"Mitozantrone","companyName":"US Department of Veterans Affairs","companyId":"us-department-of-veterans-affairs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}